Analyst Ratings For Indivior PLC (LON:INDV)
Today, Numis Securities Ltd reiterated its Buy rating on Indivior PLC (LON:INDV) with a price target of GBX 450.
There are 2 hold ratings, 5 buy ratings on the stock.
The current consensus rating on Indivior PLC (LON:INDV) is Buy (Score: 2.71) with a consensus target price of GBX 388.57 per share, a potential .
Some recent analyst ratings include
- 2/16/2017-Numis Securities Ltd Reiterated Rating of Buy.
- 2/3/2017-Stifel Nicolaus Reiterated Rating of Buy.
- 2/3/2017-Deutsche Bank AG Reiterated Rating of Buy.
- 7/19/2016-Citigroup Inc. was Downgraded by analysts at Citigroup Inc. from a “Neutral” rating to a “” rating. They now have a GBX 280 price target on the stock, up previously from GBX 230 .
About Indivior PLC (LON:INDV)
Indivior PLC (Indivior) is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and sale of prescription drugs that are based on buprenorphine for treatment of opioid dependence segment. The Company’s treatment and pipeline focuses on opioid use disorder, alcohol use disorder, overdose rescue and co-morbidities of addiction/schizophrenia. Indivior’s products, which are sold in over 40 countries, consist of Suboxone film (buprenorphine and naloxone), Suboxone tablet (buprenorphine and naloxone) and Subutex tablet (buprenorphine sublingual tablet), all of which are used to treat opioid dependence. Its Buprenorphine lifecycle includes Suboxone Tablet, Suboxone Film, Buprenorphine Monthly Depot and Oral Swallowable Capsule. Its overdose rescue product category includes Cocaine Esterase. Its alcohol use disorders product category includes Arbaclofen Placarbil. Its adjacency-schizophrenia product category includes Risperidone Monthly Depot.
Recent Trading Activity for Indivior PLC (LON:INDV)
Shares of Indivior PLC closed the previous trading session at 366.95 up +2.35 0.65% with 2,920,407 shares trading hands.
